Prior transfusion of umbilical cord mesenchymal stem cells can effectively alleviate symptoms of motion sickness in mice through interleukin 10 secretion

Figure 4 The levels of interleukin-10 and interleukin-10RA in the five groups. A: Statistical analyses of interleukin-10 (IL-10) levels in the peripheral blood in the five groups (^aP < 0.05; ^bP < 0.01; ^cP < 0.001; n = 8); B: Statistical analyses of IL-10 mRNA levels in the petrous part of temporal bone tissues of mice at four time points, normalized to mouse Gapdh (^aP < 0.05; ^bP < 0.01; n = 3); C-E: Western blot analysis showing upregulated IL-10 and IL-10RA expression in the petrous part of the temporal bone in mice of the motion sickness + mesenchymal stem cells (MS + MSCs) group compared to the MS group, and downregulated expression in the MS + AS101/MSCs group on days 3 and 5 (^aP < 0.05; ^bP < 0.01; ^cP < 0.001; n = 3). These experiments were performed three times with similar results. IL: Interleukin; MS: Motion sickness; MSCs: Mesenchymal stem cells; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.